{
  "schemaVersion": 1,
  "id": "research-015",
  "slug": "015-what-the-charcot-marie-tooth-trial-learned-from-the-ankle",
  "title": "What the Charcot-Marie-Tooth trial learned from the ankle",
  "catalogLabel": "ACE-083",
  "productCollection": "https://heritagebiolabs.com/research-library/products/ace-083",
  "productHandles": [
    "ace-083-582"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/ace-083-582"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 407,
  "sourceYears": [
    2022
  ],
  "paragraphs": [
    "Peptide bonds join amino acids into short chains called peptides. Such chains can change a cell’s activity by binding a receptor or by intercepting a signal. ACE-083 is a larger engineered protein that combines a form of follistatin with an antibody Fc region. It was investigated for local muscle growth. In an older 2022 trial, researchers asked whether targeting a muscle that lifts the front of the foot would improve mobility in adults with inherited Charcot-Marie-Tooth neuropathy. [1]",
    "Charcot-Marie-Tooth disease affects peripheral nerves, which carry instructions between the spinal cord and muscles. The tibialis anterior helps pull the foot upward at the ankle, a movement called dorsiflexion. Weakness in that movement can make it harder to clear the toes when taking a step. The trial's rationale was that an effect on the muscle might help with that part of gait even though the underlying disease involves the nerve. [1]",
    "The study first examined tolerability in an open-label phase. It then compared ACE-083 and placebo under blinded, randomized conditions over about six months. Forty-five people enrolled in the randomized phase and 44 received the assigned intervention. An MRI measure of total tibialis anterior volume was the primary endpoint. Other measures included the estimated contractile portion of the muscle, ankle strength, timed movement tests, walking distance and quality of life. [1]",
    "The trial reported an estimated 13.5% difference in change in total muscle volume favoring ACE-083 over placebo. Estimated contractile volume and a measure of ankle dorsiflexion strength also favored the intervention. The other functional outcomes did not show statistically significant improvements. Mild to moderate reactions where the study protein was administered were the most frequent adverse events. The strength result therefore belongs alongside, rather than in place of, the broader tests of movement. [1]",
    "The difference between the endpoints clarifies the study question. The MRI outcome asks how large a targeted structure became. The ankle strength outcome isolates one movement at one joint. A walking test then asks whether multiple joints, muscle groups, balance and endurance can combine to change performance. The findings show how an intervention can produce a measurable local effect without demonstrating an improvement across all three levels. They also help explain why a trial for a nerve disorder would track function even when the proposed action occurs in a muscle. A local tissue response is evidence of a biological effect under the study conditions, while improvement in mobility requires its own controlled measurement. [1]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Florian P. Thomas et al. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology (publication 2022-06-06).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35545446/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/015-what-the-charcot-marie-tooth-trial-learned-from-the-ankle",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/015-what-the-charcot-marie-tooth-trial-learned-from-the-ankle.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/015-what-the-charcot-marie-tooth-trial-learned-from-the-ankle.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 003 - ACE-031 and ACE-083.docx",
    "sourceArticleNumber": 15,
    "contentSha256": "1d5257c18a5f58942568feeafe827bff8f3d82c4f0dd653e844e192140d86650",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
